Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Immunogenicity of a Klebsiella Pneumoniae Tetravalent Bioconjugate Vaccine (Kleb4V) Administered to Healthy Adults: A FTIH Phase I/II Randomized and Controlled Study

NCT04959344 is registered in ClinicalTrials.gov with LimmaTech Biologics AG as lead sponsor.

NCT NCT04959344
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04959344 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Immunogenicity of a Klebsiella Pneumoniae Tetravalent Bioconjugate Vaccine (Kleb4V) Administered to Healthy Adults: A FTIH Phase I/II Randomized and Controlled Study
Lead sponsor
LimmaTech Biologics AG
Phase
Phase 1/2
Overall status
Completed
Start date
July 5, 2021
Completion date
September 26, 2022
Enrollment
166 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

klebsiella pneumoniae infection